COVID-19 Pneumonia Treatment Guidelines

Introduction to Azithromycin Use

• The European Respiratory Society recommends against offering azithromycin to hospitalized patients with COVID-19 in the absence of bacterial infection, based on multiple randomized controlled trials 1
• The American College of Physicians guidance recommends against using azithromycin alone or in combination with hydroxychloroquine for COVID-19 treatment due to insufficient evidence about benefits and potential harms 2

Bacterial Co-infection and Azithromycin Use

• Bacterial co-infection is reported infrequently in COVID-19 patients (<10% of cases) 1
• Azithromycin should only be considered when there is proven bacterial co-infection, strong clinical suspicion of bacterial pneumonia, or appropriate cultures obtained before antibiotic initiation 1

Risks and Considerations

• Antimicrobial resistance development from widespread use of azithromycin is a concern 1
• Potential cardiac adverse effects, especially when combined with other QT-prolonging medications, are associated with azithromycin use 1
• Unnecessary medication exposure and side effects without clinical benefit can occur with azithromycin use in COVID-19 patients 1

Antibiotic Use in COVID-19 Patients with Bacterial Pneumonia

• If bacterial pneumonia is suspected or confirmed in a COVID-19 patient, obtain appropriate cultures before starting antibiotics, consider local resistance patterns, and choose appropriate antibiotics based on suspected pathogens 3
• For community-acquired pneumonia, consider a beta-lactam plus a macrolide for hospitalized patients 3

Evidence-Based Recommendations

• The recommendation against azithromycin for COVID-19 is based on multiple randomized controlled trials showing no benefit, systematic reviews and meta-analyses, and guidelines from respected organizations (ERS, American College of Physicians) 1
• The most recent and highest quality evidence consistently shows no mortality benefit, no reduction in hospital stay, and no improvement in clinical status with azithromycin use for COVID-19 pneumonia 1